Jonas Hallen

Oslo, Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

A first-in-human study of CAL101, a monoclonal antibody targeting S100A4.

A first-in-human study of CAL101, a monoclonal antibody targeting S100A4.

Journal: British journal of clinical pharmacology

Published: April 01, 2026

Development of CAL101-a humanized monoclonal antibody targeting S100A4 to inhibit proinflammatory and profibrotic signaling.

Development of CAL101-a humanized monoclonal antibody targeting S100A4 to inhibit proinflammatory and profibrotic signaling.

Journal: The Journal of pharmacology and experimental therapeutics

Published: June 24, 2025

Reply.

Reply.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: January 29, 2024

Effect of Anti-S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis-Specific Transcriptional Signatures in Human Skin.

Effect of Anti-S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis-Specific Transcriptional Signatures in Human Skin.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: February 22, 2023

S100A4-neutralizing monoclonal antibody 6B12 counteracts the established experimental skin fibrosis induced by bleomycin.

S100A4-neutralizing monoclonal antibody 6B12 counteracts the established experimental skin fibrosis induced by bleomycin.

Journal: Rheumatology (Oxford, England)

Published: February 17, 2023

Clinical and pathogenic significance of S100A4 overexpression in systemic sclerosis.

Clinical and pathogenic significance of S100A4 overexpression in systemic sclerosis.

Journal: Annals of the rheumatic diseases

Published: January 07, 2023

Adherence and persistence to pharmacotherapy in patients with heart failure: a nationwide cohort study, 2014-2020.

Adherence and persistence to pharmacotherapy in patients with heart failure: a nationwide cohort study, 2014-2020.

Journal: ESC heart failure

Published: April 27, 2022

A nationwide registry study on heart failure in Norway from 2008 to 2018: variations in lookback period affect incidence estimates.

A nationwide registry study on heart failure in Norway from 2008 to 2018: variations in lookback period affect incidence estimates.

Journal: BMC cardiovascular disorders

Published: April 14, 2021

Incidence, prevalence, and mortality of heart failure: a nationwide registry study from 2013 to 2016.

Incidence, prevalence, and mortality of heart failure: a nationwide registry study from 2013 to 2016.

Journal: ESC heart failure

Published: October 30, 2019

Reproducibility of in-hospital worsening heart failure event adjudication in the RELAX-AHF-EU trial.

Reproducibility of in-hospital worsening heart failure event adjudication in the RELAX-AHF-EU trial.

Journal: European journal of heart failure

Published: May 24, 2019

Increases in Circulating Cardiac Troponin Are Not Always Associated with Myocardial Cell Death.

Increases in Circulating Cardiac Troponin Are Not Always Associated with Myocardial Cell Death.

Journal: Clinical laboratory

Published: December 15, 2018

Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU.

Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU.

Journal: European journal of heart failure

Published: July 10, 2018

Showing 1-12 of 28

Last Updated: 09/26/2026